Literature DB >> 28592961

Predisposing factors for atrial fibrillation in the elderly.

Kristina Wasmer1, Lars Eckardt1, Günter Breithardt1.   

Abstract

Atrial fibrillation (AF) in the elderly occurs as a consequence of cardiovascular aging and an age related increase of comorbidity. Several predisposing factors for AF have been identified for the overall AF population. Most of them, cardiovascular disease in particular, play a role in younger and older patients. The longer time period during which these risk factors can cause structural changes that ultimately lead to AF may, at least in part, explain the association between age and AF. In addition, less well defined age-related changes in cellular electrophysiologic properties and structure predispose to AF in the elderly.

Entities:  

Keywords:  Atrial fibrillation; Atrial fibrosis; Mechanisms; Risk factors; Stroke; The elderly

Year:  2017        PMID: 28592961      PMCID: PMC5460064          DOI: 10.11909/j.issn.1671-5411.2017.03.010

Source DB:  PubMed          Journal:  J Geriatr Cardiol        ISSN: 1671-5411            Impact factor:   3.327


Introduction

Atrial fibrillation (AF) is the most frequent clinically significant arrhythmia and its incidence is continuously rising.[1] This increase is at least in part due to the aging of the population. Studies have also demonstrated an increase in AF incidence after age adjustment, which is probably a reflection of comorbidities and cardiovascular risk factors, in addition to other factors such as lifestyle changes.[1],[2] It is expected that in the European Union the number of subjects age ≥ 55 years with AF will more than double between 2010 and 2060, from 8.8 to 17.9 million.[3] Likewise, it is expected that in the US more than 5.6 million people will have AF in 2050, and half of them will be older than 80 years.[4] The anticipated increase in AF may also be related to an earlier and more frequent diagnosis across all age groups due to better awareness of the arrhythmia and its complications and more frequent ECG monitoring over longer periods of time. In addition, improved treatment and subsequently improved survival of patients with cardiovascular disease may lead to an increase in individuals with AF compared to the past. The association of AF with increasing age is well recognized and has been shown by several epidemiological studies.[5]–[7] The risk of developing AF doubles with each progressive decade of gaining and exceeds 20% by age 80 years.[8] Although important and well established, age is not the only risk factor associated with AF. The arrhythmia shows wide heterogeneity regarding comorbidities and age.[9] While it is observed frequently in older patients, it is also observed in young people and those without any comorbidity. AF etiology in the elderly likely differs from younger patients.[10] The EORP-AF general pilot registry was designed to gain information regarding AF management in Europe. Based on these registry data, Fumagalli, et al.,[11] analyzed differences in presentation, co-morbidities and treatment of AF according to age. One third of patients in this registry, more than 1000 were ≥ 75 years of age. Older patients more often had persistent or permanent AF compared with younger patients. They also had a higher prevalence of comorbidities, including coronary artery disease, chronic heart failure including a substantial proportion of patients with heart failure with preserved ejection fraction, chronic kidney disease, chronic obstructive pulmonary disease (COPD), valvular heart disease and hypertension. Previous hemorrhagic events and transient ischemic attack (TIA) were reported more often in older patients. All these comorbidities led to higher CHA2DS2-VASc and HAS-BLED scores. With regard to symptoms, older patients reported palpitations less frequently, but reported dyspnea more often. They appeared to do better with rate rather than rhythm control,[12] which was also the preferred management in older patients.[11] This article summarizes risk factors for AF and associated pathophysiological changes, both in the general AF population, and with respect to the elderly patient.

Risk factors for development of AF

For the overall population, several risk factors for AF development have been identified. They all contribute to AF, each factor individually, and in combination with each other.[13] Risk factors for incident AF (after age-adjustment) in the Framingham cohort were cigarette smoking, diabetes mellitus, hypertension, and prevalent CAD. Combined, they explained 44% of the burden of AF in men and 58% in women.[14] The absolute and attributable risks of AF in relation to optimal and borderline risk factors were studied in The Atherosclerosis Risk in Communities (ARIC) Study.[15] Overall, 56.5% of AF cases could be explained by one borderline or elevated risk factor of which elevated blood pressure was the most important contributor.[16] Thus, in a high number of cases, AF is associated with acquired risk factors that should be amenable to preventive measures. While some risk factors are well established, others are rather new. Because different risk factors may cause the same electrical and structural changes that predispose for AF and several factors are frequently present in an individual patient, quantification of a given factor's specific impact on AF development is a futile effort. Across all age groups, the incidence of AF is higher in men than in women.[5] It is unknown whether this difference is due to sex itself or just a phenomenon of under-diagnosed AF in women and/or over-diagnosed AF in men due to different symptom intensity or/and differing medical attention. Hypertension is the number one risk factor globally.[2] The higher the blood pressure, the greater is the risk for incident AF.[13],[17] Like hypertension, heart failure is associated with an increase in atrial pressure and/or volume overload and diastolic ventricular dysfunction, which may lead to atrial dilatation and fibrosis, the electrical and structural changes providing the basis for AF development. While hypertension is an important and well established risk factor for AF, heart failure is less well defined and has not been studied as extensively. Valvular heart disease, particularly left sided disease, leads to atrial pressure and volume overload and is associated with AF development. Both passive atrial stretch and an increase in atrial pressure during atrial contraction have been found to stimulate the release of atrial natriuretic factor. The level of this neurohormonal activation was found to be a predictor of paroxysmal AF. Diabetes mellitus and hyperthyroidism have also been recognized as independent risk factors for AF. Coronary artery disease and chronic kidney disease are risk markers for AF as well.[14],[18] High body mass index (BMI) which is often associated with sleep apnea ranks sixth in the global list.[2] High BMI is also associated with increased left atrial volume. COPD appears to be associated with progression from paroxysmal to persistent and permanent AF. Less well-established risk factors are tall stature, increased epicardial fat, high birth weight, alcohol consumption, smoking and high-level endurance training. Obesity has recently received increasing attention as a risk factor for AF based on epidemiological, mechanistic and clinical evidence.[19] It carries a strong link to metabolically active atrial epicardial fat tissue.[20] Genetic factors, both monogenic and polygenic, have recently been identified as risk factors for AF. A positive family history of AF nearly doubles the risk of developing AF.[21] Early-onset AF in particular appears to have a strong heritable component that is independent of concomitant cardiovascular conditions.[22],[23] Up to one third of AF patients carry common genetic variants that predispose to AF. Inflammation has been suggested as pathophysiological mechanism in AF development and perpetuation.[24] The causal role of inflammation in structural atrial damage has been reinforced by experimental studies.[23] Inflammation has been studied predominantly in post-operative AF, and its role is less well established for other forms of AF. Left atrial (LA) enlargement has also been described as risk factor for AF.[18] In a study by Tsang, et al.,[25] LA volume was confirmed to be independent of both clinical risk factors and diastolic function profile for the prediction of AF. Whether LA enlargement is the hen or the egg with regard to AF is not known, only patients with new onset of AF were included in the study. Still it is possible that patients already had asymptomatic episodes of AF over some time that led to left atrial enlargement. There is also an association between sick sinus syndrome (SSS) and AF. Like AF, SSS is diagnosed more often in men, increases with age and is associated with several cardiovascular risk factors like hypertension, diabetes and higher body mass index.[26] In addition, SSS can have a genetic background. It can manifest as bradycardia with or without tachycardia-bradycardia syndrome.[27] Both forms of SSS, with and without tachycardia-bradycardia syndrome, are correlated with severe structural and electrical remodeling, thereby predisposing for AF. Recently, advanced interatrial block, first described by Bayes de Luna., et al.,[28] has been shown in the ARIC study to be associated with an increased risk for AF after adjustment for socio-demographics, cardiovascular risk factors, and potential confounders.[29] Cardiovascular comorbidities and other risk factors as well as AF itself induce a slow but progressive process of structural remodeling in the atria.[22] Activation of fibroblasts, enhanced connective tissue deposition, and fibrosis are the hallmarks of this process. In addition, atrial fatty infiltrations, inflammatory infiltrates, myocyte hypertrophy, necrosis and amyloidosis are found in patients with concomitant conditions predisposing to AF. In many patients, the structural remodeling process occurs before the onset of AF.[22] In addition to structural changes, AF induces electrical and autonomic tone remodeling. The relative contribution of underlying primary conditions versus AF itself to the clinical progression of AF is presently unclear.[30] In the German Atrial Fibrillation Network (AFNET) registry, the likelihood that patients had persistent or permanent AF increased with the number of risk factors in a given patient.[31] The “HATCH” score, including the risk factors heart failure, age, previous TIA or stroke, COPD and hypertension, was proposed to identify patients with AF progression.[32] This emphasizes the fact that several risk factors typically coexist and act in combination. The impact of each risk factor may vary by age. Genetic factors, obesity and endurance sports likely play a larger role in younger patients, while other factors are more prevalent and relevant in older patients. Their contribution to AF in an individual patient, especially in combination with the risk factor “age” which discussed below, is unknown, but likely depends on disease severity and consequent treatment.

“Age” as a risk factor for AF

Aging involves a relentless and systematic process of degeneration in living organisms leading to attenuation of most biochemical and physiological functions.[33] “Age” as risk factor remains to be defined and the rate at which aging occurs is different between individuals. Most studies define “elderly” as those patients older than 65 years.[18] At the same time, it is generally accepted that calendar age and biological age are not synonymous. At least from an epidemiological standpoint, there is a marked increase in AF between 60 and 65 years (Figure 1).[33]
Figure 1.

Depiction of the AF prevalence in different studies.

There is a steep increase in AF prevalence across all studies between 60 and 65 years of age (red line). Adjusted from citation [31] with permission. AF: atrial fibrillation.

It is well known that aging increases the propensity for occurrence of AF.[34],[35] The pathophysiologic mechanisms, though, by which aging increases the likelihood for AF development remain poorly understood.[36] A longer time period during which the atrial myocardium is exposed to external stressors, i.e., risk factors, likely plays a role in the association of age and AF as well. Most elderly patients present with one or more comorbidities. It appears very difficult if not impossible to distinguish the impact of these comorbidities from true “age” related factors.

Depiction of the AF prevalence in different studies.

There is a steep increase in AF prevalence across all studies between 60 and 65 years of age (red line). Adjusted from citation [31] with permission. AF: atrial fibrillation. There are only limited experimental and even less clinical data that relate to “age” as a predisposing factor for AF despite the overwhelming evidence of the close association between increasing age and AF. While AF generally is more prevalent in men than in women in the AFNET registry, women outnumber men in the age group above 80years,[31] likely because they live longer than men. Since men typically acquire more cardiovascular risk factors, it could be hypothesized, that theses comorbidities play a larger role for AF than the risk factor “age”. The atrial myocardium undergoes electrical and structural remodeling with age, both of which may play an important role in the initiation and/or perpetuation of atrial arrhythmias.[34],[37] Changes in atrial tissue structure appear to be of major importance in providing a substrate for AF. Structurally aged atrial bundles are characterized by enhancement of the fibrous tissue that is interspersed between myocytes.[34] Cardiac fibrosis is characterized by excessive accumulation of fibrillary collagen in the extracellular space. It may result from age-dependent cardiomyocyte loss (replacement fibrosis),[38] or it may be an interstitial response to chronic diseases such as hypertension, myocarditis, and congestive heart failure (reactive fibrosis).[34] Fibrosis is ubiquitous in the atria of the aging heart and the hallmark of the structural AF substrate.[30] Both, increased non-uniform atrial interstitial fibrosis[39] and atrial conduction slowing have been shown in patients with AF.[40] Age-related electrical changes due to ionic current alterations include modifications in the cellular action potential shape and duration as well as an enhanced dispersion of cardiac repolarization.[34] This has been shown in canine models and in human tissue. Anyukovsky, et al.,[41] showed that conduction velocity for premature beats was reduced in older canine hearts and occurred during a wider time window. Again, they found a twofold increase in the amount of fibrous tissue. In a rat model, Hayashi, et al.,[42] showed that old rats had significantly longer interatrial conduction time and P wave durations compared with young rats. AF was inducible in old rats, but not young rats. As reported by others, histology revealed a significant increase in interstitial atrial fibrosis, atrial cell size, and heart weight. Arterial stiffness increases with age and predicts coronary artery disease, stroke and mortality.[43] Fumagalli, et al.,[44] reported a significant association between arterial stiffness (measured as cardio-ancle vascular index on both upper and lower extremities) and age in a small group of patients. Of note, this index was not affected by hypertension, coronary artery disease, cerebrovascular disease, chronic renal failure and heart failure, all known to be risk factors for AF. Arterial stiffness was also associated with increased left atrial diameters, but the exact interaction between arterial stiffness, left atrial and left ventricular properties (i.e., stiffness) could not be fully explained by their observations. The majority of AF cases may be the consequence of risk factors causing increased arterial stiffness, diastolic dysfunction, and atrial volume overload.[45],[46] Recently, the association between age-related arterial stiffness and persistence or recurrence of AF has been studied.[46] For each one-unit increase in cardio-ancle vascular index, the risk of finding AF at the control visit was 2.31 times higher. When using pulse pressure as marker of arterial stiffness, participants of the Framingham Heart Study were found to have an increased risk for AF as well.[47] Diastolic left ventricular dysfunction with abnormal left ventricular relaxation is very common in the elderly and has been regarded as part of the normal aging process.[48] Although this form of left ventricular relaxation abnormality is considered the mildest one, patients with this form of diastolic dysfunction have a greater risk for AF independent of the effects of age. Pathophysiologically, LV relaxation abnormalities may lead to the development of higher atrial pressures during atrial diastole by reducing passive LA emptying. Over time, LA and pulmonary veins could dilate and potentiate electrical and structural remodeling thereby increasing vulnerability to AF. In a study by Tsang, et al.,[25] the diastolic dysfunction profile was incremental to clinical risk factors and left atrial volume. Furthermore, the gradient of risk appeared to be related to the severity of diastolic dysfunction.

AF progression

AF is typically seen as a progressive arrhythmia, where structural and electrophysiological changes lead to persistent and permanent AF over time. This progression, though, differs widely between patients. Progression of AF from paroxysmal to persistent is faster in older patients and those with underlying heart disease.[30],[49] Saksena, et al.,[50] analyzed data of patients (mean age of 70 ± 10 years) with paroxysmal AF and a dual chamber pacemaker. AF progression was observed in 24% of patients and associated with a progressive increase in AT (atrial tachyarrhythmia)/AF burden. This increase was highly correlated with the presence of structural heart disease, which was interpreted as a relation between AF progression and substrate rather than trigger-based progression. Still it remains unclear, why paroxysmal AF may remain self-terminating for decades in some patients, but progresses to persistent AF within weeks in others.[50]
  50 in total

Review 1.  Pathophysiology and prevention of atrial fibrillation.

Authors:  M A Allessie; P A Boyden; A J Camm; A G Kléber; M J Lab; M J Legato; M R Rosen; P J Schwartz; P M Spooner; D R Van Wagoner ; A L Waldo
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

2.  Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women.

Authors:  Teresa S M Tsang; Bernard J Gersh; Christopher P Appleton; A Jamil Tajik; Marion E Barnes; Kent R Bailey; Jae K Oh; Cynthia Leibson; Samantha C Montgomery; James B Seward
Journal:  J Am Coll Cardiol       Date:  2002-11-06       Impact factor: 24.094

Review 3.  The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg.

Authors:  Alan S Go
Journal:  Am J Geriatr Cardiol       Date:  2005 Mar-Apr

4.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

5.  Lifetime risk for development of atrial fibrillation: the Framingham Heart Study.

Authors:  Donald M Lloyd-Jones; Thomas J Wang; Eric P Leip; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Ralph B D'Agostino; Joseph M Massaro; Alexa Beiser; Philip A Wolf; Emelia J Benjamin
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

6.  Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring.

Authors:  Caroline S Fox; Helen Parise; Ralph B D'Agostino; Donald M Lloyd-Jones; Ramachandran S Vasan; Thomas J Wang; Daniel Levy; Philip A Wolf; Emelia J Benjamin
Journal:  JAMA       Date:  2004-06-16       Impact factor: 56.272

7.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.

Authors:  Jan Heeringa; Deirdre A M van der Kuip; Albert Hofman; Jan A Kors; Gerard van Herpen; Bruno H Ch Stricker; Theo Stijnen; Gregory Y H Lip; Jacqueline C M Witteman
Journal:  Eur Heart J       Date:  2006-03-09       Impact factor: 29.983

8.  Aging-related increase to inducible atrial fibrillation in the rat model.

Authors:  Hideki Hayashi; Charles Wang; Yasushi Miyauchi; Chikaya Omichi; Hui-Nam Pak; Shengmei Zhou; Toshihiko Ohara; William J Mandel; Shien-Fong Lin; Michael C Fishbein; Peng-Sheng Chen; Hrayr S Karagueuzian
Journal:  J Cardiovasc Electrophysiol       Date:  2002-08

9.  Risks for atrial fibrillation and congestive heart failure in patients >/=65 years of age with abnormal left ventricular diastolic relaxation.

Authors:  Teresa S M Tsang; Marion E Barnes; Bernard J Gersh; Kent R Bailey; James B Seward
Journal:  Am J Cardiol       Date:  2004-01-01       Impact factor: 2.778

10.  Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis.

Authors:  Evgeny P Anyukhovsky; Eugene A Sosunov; Alexei Plotnikov; Ravil Z Gainullin; Jeffrey S Jhang; Charles C Marboe; Michael R Rosen
Journal:  Cardiovasc Res       Date:  2002-05       Impact factor: 10.787

View more
  21 in total

1.  Afterdepolarizations and abnormal calcium handling in atrial myocytes with modulated SERCA uptake: a sensitivity analysis of calcium handling channels.

Authors:  Andy C Y Lo; Jieyun Bai; Patrick A Gladding; Vadim V Fedorov; Jichao Zhao
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2020-05-25       Impact factor: 4.226

Review 2.  Stroke Risk in Atrial Fibrillation: Beyond the CHA2DS2-VASc Score.

Authors:  Pooja S Jagadish; Rajesh Kabra
Journal:  Curr Cardiol Rep       Date:  2019-07-27       Impact factor: 2.931

3.  Enlarged left atrium and decreased left atrial strain are associated with atrial fibrillation in patients with hyperthyroidism irrespective of conventional risk factors.

Authors:  Dong Geum Shin; Min-Kyung Kang; Donghoon Han; Seonghoon Choi; Jung Rae Cho; Namho Lee
Journal:  Int J Cardiovasc Imaging       Date:  2021-10-27       Impact factor: 2.357

Review 4.  Genetic and non-genetic risk factors associated with atrial fibrillation.

Authors:  Lindsay J Young; Steve Antwi-Boasiako; Joel Ferrall; Loren E Wold; Peter J Mohler; Mona El Refaey
Journal:  Life Sci       Date:  2022-04-03       Impact factor: 6.780

5.  Connexins and Atrial Fibrillation in Obstructive Sleep Apnea.

Authors:  Abdelnaby Khalyfa; David Gozal
Journal:  Curr Sleep Med Rep       Date:  2018-10-26

6.  Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older.

Authors:  Patrick Manckoundia; Gilles Nuemi; Arthur Hacquin; Didier Menu; Clémentine Rosay; Jérémie Vovelle; Valentine Nuss; Camille Baudin-Senegas; Jérémy Barben; Alain Putot
Journal:  Int J Environ Res Public Health       Date:  2021-04-22       Impact factor: 3.390

7.  Clinical characteristics and type of antithrombotic treatment in a Spanish cohort of elderly patients with atrial fibrillation according to dependency, frailty and cognitive impairment.

Authors:  Jose María Mostaza; Manuel Jesús Romero Jiménez; Fernando José Ruiz Laiglesia; José Antonio Díaz Peromingo; Manuel Beltrán Robles; Ernesto Guevara Sierra; Ana Santander Bilbao; Carmen Suárez
Journal:  J Geriatr Cardiol       Date:  2018-04       Impact factor: 3.327

Review 8.  Mitochondrial Dysfunction in Atrial Fibrillation-Mechanisms and Pharmacological Interventions.

Authors:  Paweł Muszyński; Tomasz A Bonda
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

9.  Is Atrial Fibrillation a Risk Factor for Worse Outcomes in Severe COVID-19 Patients: A Single Center Retrospective Cohort.

Authors:  Abdulkarim Abdulrahman; Tajammul Hussain; Safraz Nawaz; Shereen AlShaikh; Abdulrahman Almadani; Fawaz Bardooli
Journal:  J Saudi Heart Assoc       Date:  2021-02-17

10.  Thyroid Hormone Resistance in Identical Twin Sisters with Atrial Fibrillation: Case Report and Review of the Literature.

Authors:  Mark B Zimering
Journal:  J Endocrinol Diabetes       Date:  2018-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.